EW
MRNA icon

Evoke Wealth’s Moderna MRNA Stock Holding History

Evoke Wealth’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-239
Closed -$28K – 842
2022
Q3 		$28K Buy
239
+120
+101% +$18.2K ﹤0.01% 596
2022
Q2 		$17K Sell
119
-42
-26% -$6K ﹤0.01% 685
2022
Q1 		$28K Buy
161
+24
+18% +$4.04K ﹤0.01% 599
2021
Q4 		$35K Buy
137
+36
+36% +$10.5K ﹤0.01% 583
2021
Q3 		$38K Buy
101
+15
+17% +$5.53K ﹤0.01% 543
2021
Q2 		$20K Sell
86
-63
-42% -$11.3K ﹤0.01% 659
2021
Q1 		$20K Buy
149
+88
+144% +$12.8K ﹤0.01% 591
2020
Q4 		$6K Hold
61
– – ﹤0.01% 683
2020
Q3 		$4K Hold
61
– – ﹤0.01% 721
2020
Q2 		$4K Sell
61
-1,000
-94% -$54.8K ﹤0.01% 735
2020
Q1 		$31.8K Buy
1,061
+61
+6% +$1.4K ﹤0.01% 378
2019
Q4 		$19.6K Hold
1,000
– – ﹤0.01% 595
2019
Q3 		$15.9K Buy
+1,000
New +$14.8K ﹤0.01% 715

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Evoke Wealth's MRNA Position: Q4 2022 in Review

Evoke Wealth sold out of Moderna (MRNA) in Q4 2022, closing a stake of 239 shares — an estimated $28K sold.

Evoke Wealth first reported a position in MRNA in Q3 2019 and held it in 13 quarters. The position peaked at $38K in Q3 2021. 1,071 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

  • Evoke Wealth reported no remaining Moderna position as of Q4 2022 after selling out during the quarter.
  • Evoke Wealth sold 239 Moderna shares in Q4 2022, an estimated $28K.
  • Evoke Wealth first reported a position in Moderna in Q3 2019 and held it in 13 quarters.
  • Evoke Wealth's Moderna position peaked at $38K in Q3 2021.
  • 1,071 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on Evoke Wealth's 13F filing for Q4 2022, filed 10 Feb 2023.